OGHALE MUKORO: Open Payments
NPI 1437666591 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,550 in 119 payments from 17 companies in 2025. Trend: 2023 $1,557 · 2024 $1,709 · 2025 $2,550
Food & beverage: $2,550
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $439 |
| Otsuka America Pharmaceutical, Inc. | 16 | $281 |
| Axsome Therapeutics, Inc. | 7 | $223 |
| ABBVIE INC. | 11 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $198 |
| Teva Pharmaceuticals USA, Inc. | 11 | $187 |
| Neurocrine BioSciences, Inc. | 8 | $178 |
| Alkermes, Inc. | 7 | $172 |
| E.R. Squibb & Sons, L.L.C. | 7 | $153 |
| Lundbeck LLC | 7 | $135 |
Products named: CAPLYTA, REXULTI, Auvelity, VRAYLAR, TRINTELLIX, INGREZZA, ARISTADA, COBENFY.
Industry payments across TX — which companies pay providers there.
